Amitiza (lubiprostone)
/ Takeda, Mallinckrodt
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
283
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
February 13, 2026
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
(clinicaltrials.gov)
- P2 | N=124 | Not yet recruiting | Sponsor: Sun Yat-sen University
New P2 trial • Colon Cancer • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor
February 02, 2026
Real-World Safety Analysis of the Constipation-Predominant IBS Treatment Options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor.
(PubMed, Gastroenterol Hepatol (N Y))
- No abstract available
Journal • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder
January 31, 2026
Comparison of Polyethylene Glycol Combined with Lubiprostone versus Standard-Dose Polyethylene Glycol for Bowel Preparation Before Colonoscopy in Patients with Chronic Constipation: A Multicenter Randomized Controlled Trial
(ChiCTR)
- P=N/A | N=462 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
New trial • Constipation • Gastroenterology • Gastrointestinal Disorder
December 24, 2025
PGE1 Suppresses the Expression of M2 Markers on Macrophages Through Prostaglandin Receptors.
(PubMed, Cells)
- "PGE1 decreased M2 marker expression in heterospheroids more effectively compared with PGE2, PGE3, misoprostol, and 13,14-dihydro-15-keto-PGE1, whereas the suppressive effects of 15-keto- and 13,14-dihydro-PGE1s, and lubiprostone were comparable to that of PGE1. Pharmacological inhibition of prostaglandin receptors revealed that EP2 and EP4 receptors are involved in the PGE1-induced reprogramming of M2-like macrophages to M1 macrophages. In summary, PGE1 and its derivatives are promising TAM-targeting immunotherapeutics."
Biomarker • IO biomarker • Journal • Liver Cancer • Oncology • Solid Tumor • CXCR2
December 12, 2025
STOPS 03: Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
(clinicaltrials.gov)
- P3 | N=346 | Recruiting | Sponsor: Third Military Medical University
New P3 trial • Constipation • Gastroenterology • Gastrointestinal Disorder
December 05, 2025
Effect of Multiple Pharmacological Interventions and Magnetic Control on Capsule Endoscopy Gastrointestinal Transit Time and Diagnostic Yield: A Systematic Review and Meta-Analysis.
(PubMed, JGH Open)
- "Erythromycin and magnetic guidance were consistently associated with faster gastric passage, while lubiprostone and polyethylene glycol (PEG) shortened SBTT compared with control groups. For improving overall completion, metoclopramide remains a dependable option. These findings support individualized preparation strategies tailored to the specific diagnostic goals of CE."
Journal • Retrospective data
November 20, 2025
Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.
(PubMed, J Neurogastroenterol Motil)
- "First line therapies such as dietary-fiber optimization and osmotic laxatives are widely available, but newer pharmacotherapies (prucalopride, linaclotide, lubiprostone, and elobixibat) remain costly and unevenly accessible. The Bali Chronic Constipation Roundtable highlighted Asia's need for region specific diagnostics and management. Addressing diagnostic and treatment gaps will improve outcomes, while ongoing researcher clinician policy collaboration must standardize guidelines, advance research, and ensure equitable care across Asia."
Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
November 03, 2023
Bioelectric Reprogramming of the Bone Marrow Niche in Acute Myeloid Leukemia
(ASH 2023)
- "On the contrary, we treated AML-MSCs with hyperpolarizing agents (lubiprostone and ivermectin), which reverted their phenotype to that of h-MSCs, including lower proliferation level (ivermectin -1.9-fold, p<0.05), higher immunomodulatory potential, and higher CaV1.2 levels (1.8-fold by flow cytometry, p<0.05) with respect to untreated AML-MSCs, suggesting that depolarization is reversible and that by modeling MSCs Vmem we can restore an healthy stroma within the BM niche...In addition, we unveiled CaV1.2 channels as a key player in this process and postulated that rewriting the bioelectric code of the patient' AML-MSCs, through the restoration of voltage-dependent calcium channel CaV1.2 activity, could be a strategy to restore their healthy phenotype. These findings provide the biological rationale to evaluate the potential of novel MSCs gene or pharmacological therapies that could both disadvantage AML progression and restore a permissive BM niche."
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • IL6
October 18, 2025
Lubiprostone in CKD: Insights into Mitochondrial Function and Polyamines from a Randomized Phase 2 Clinical Trial
(KIDNEY WEEK 2025)
- "Key findings of this work are under revision for publication. Clinical Trials Registry Number: UMIN000023850"
Clinical • P2 data • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease
November 08, 2025
Regulation and mechanism of chloride channels in proliferative vitreoretinopathy.
(PubMed, Medicine (Baltimore))
- "By reducing the opening of chloride channels within RPE cells via drugs, PVR formation can be suppressed, which is sufficient to counteract retinal degeneration. Chloride channels may have crucial effects on RPE cell proliferation and migration. The therapeutic strategy of blocking chloride channels may be beneficial for PVR."
Journal • Ophthalmology • Retinal Disorders • TGFB1
October 31, 2025
Efficacy of Lubiprostone in Preventing Constipation After Total Knee Arthroplasty: A Multicenter, Prospective, Randomized Controlled Trial
(ChiCTR)
- P4 | N=212 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P4 trial • Constipation • Gastroenterology • Gastrointestinal Disorder • Orthopedics • Pain
August 30, 2025
Combined Efficacy of Methylnaltrexone and Naloxegol in Managing a Case of Neurogenic and Opioid-Induced Constipation
(ACG 2025)
- "His bowel regimen is polyethylene glycol 17g 3 times a day, lubiprostone 24mcg daily, 2 tablet of senna 8.6mg twice daily, and naloxegol 12.5mg daily. (2020), which show methylnaltrexone's efficacy in opioid-treated patients. While promising, further research is needed to assess the long-term safety and efficacy of this combined approach in similar patient populations."
Clinical • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease • Multiple Sclerosis
August 30, 2025
Real-World Safety Analysis of the Constipation-Predominant Irritable Bowel Syndrome Treatment Options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor
(ACG 2025)
- "Linaclotide was suspected of frequently inducing diarrhea (n=2,082, 24.1%), abdominal pain (n=815, 9.4%), abdominal bloating (n=795, 9.2%), and nausea/vomiting (n=266, 3.1%). Plecanatide was suspected of frequently inducing diarrhea (n=137, 20.4%), abdominal pain (n=76, 11.3%), abdominal bloating (n=62, 9.2%), and nausea/vomiting (n=34, 5.1%). Tenapanor was suspected of frequently inducing diarrhea (n=51, 32.9%), abdominal pain (n=13, 8.4%), and abdominal bloating and nausea/vomiting (n=11 each, 7.1%)."
Clinical • Real-world • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder • Pulmonary Disease
August 30, 2025
Rectal Bleeding as the Initial Presentation of Prostate Adenocarcinoma With Direct Rectal Invasion: A Case Report
(ACG 2025)
- "Current treatment includes both radiation therapy and hormonal therapy with lubiprostone. This case highlights the need to consider prostate cancer with rectal invasion as a potential cause in elderly male patients presenting with rectal bleeding and rectal masses that appear atypical for primary colorectal...A multidisciplinary approach is essential for effective management.Figure: Prostate mass directly invading the rectumFigure: A. Hematoxylin and Eosin, 400XB. Prostate specific antigen immunization (Ventana, Roche, Tucson, Arizona), 400X"
Case report • Clinical • Colorectal Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • ACPP • CDX2 • PSAP
August 30, 2025
Outpatient Management of Partial Small Bowel Obstruction Using an Oral Palatable Elemental Diet
(ACG 2025)
- "Given her prior postoperative complications, she has been understandably hesitant to undergo surgical lysis of adhesions.Episodes of pSBO would occur despite multiple gut-directed treatments including lubiprostone, linaclotide, plecanatide, pyridostigmine, and rifaximin daily. Elemental diets provide complete nutrition with high absorptive efficiency in the proximal small bowel. Being fiber- and residue-free, they present an intriguing option for the conservative management of partial bowel obstruction.Figure: Figure 1) Serial abdominal radiographs demonstrating the progression and resolution of partial small bowel obstruction in response to outpatient exclusive elemental diet consumption in 2024.Figure: Figure 2) Serial abdominal radiographs demonstrating the progression and resolution of partial small bowel obstruction in response to outpatient elemental diet consumption in 2025."
Clinical
August 30, 2025
Chronic Constipation and Small Bowel Obstruction as a Complication of Uterine Fibroids
(ACG 2025)
- "Trials of lubiprostone and linaclotide did not provide relief. UAE was successfully performed, leading to symptomatic relief and resolution of the obstruction without the need for surgical resection. This case underscores the importance of considering pelvic pathology in the differential diagnosis of bowel obstruction and chronic constipation in women and demonstrates the utility of UAE as a minimally invasive, fertility-sparing therapeutic option in select patients.Figure: Uterine Fibroids Causing Sigmoid NarrowingFigure: CT Coronal View Uterine Fibroids"
Constipation • Gastroenterology • Gastrointestinal Disorder • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health
August 30, 2025
New Kid on the Block: Could Suzetrigine's Promise of Pain Relief Improve Outcomes in Management of DGBI?
(ACG 2025)
- "He tried linaclotide, plecanatide, lubiprostone, prucalopride, and tenapanor...Adjunct pharmacological neuromodulators like nortriptyline, duloxetine and gabapentin were not helpful...She responded partially to duloxetine, buspirone, mirtazapine, and cognitive behavioral therapy...Studies have directly and indirectly established the importance of NaV1.8 to visceral pain perception (Table 1). Additional trials are needed to evaluate the impact of this medicine on visceral pain perception especially in conditions associated with acute and/or chronic abdominal pain, including DGBIs.Figure: Summary of Studies Supporting the Role of Nav1.8 in Visceral Pain Perception"
Cardiovascular • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pain • Psychiatry • NAV1
October 30, 2025
Cost-utility analysis of treatment strategies for chronic constipation in Japan.
(PubMed, J Gastroenterol)
- "The lubiprostone-elobixibat-PEG formulation strategy showed the most favorable cost-effectiveness profile. In addition, novel treatment options, including lubiprostone, linaclotide, elobixibat, and PEG formulation, were found to be cost-effective compared to MgO. Further research is warranted to confirm these findings and support their application in clinical practice."
HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
July 01, 2025
GUILLAIN-BARRÉ SYNDROME SECONDARY TO WEST NILE VIRUS IN WEST VIRGINIA
(CHEST 2025)
- "Additionally, he received antibiotics for Haemophilus influenza pneumonia and was diagnosed with Ogilvie syndrome, which improved with bowel regimen and Lubiprostone... This case emphasizes the need for healthcare providers to remain vigilant for WNV in patients presenting with GBS symptoms, even in regions where its prevalence is low."
Cough • Immunology • Infectious Disease • Influenza • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Sinusitis
October 22, 2025
Socioeconomic value of treatments for chronic idiopathic constipation in Japan.
(PubMed, BMC Gastroenterol)
- "Considering CIC-related medical costs, QoL, productivity loss, and caregiver burden, elobixibat 10 mg is associated with better QoL and lower costs than linaclotide 0.5 mg and lubiprostone 48 μg."
Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
October 17, 2025
Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis.
(PubMed, Lancet Child Adolesc Health)
- "Polyethylene glycol is probably more effective than placebo and key comparator therapies and should be considered the standard of first-line care. Future studies should consider polyethylene glycol as an index therapy, and clearly describe methods, patient characteristics, and previous therapeutics."
Journal • Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder
October 13, 2025
Efficacy and safety of lubiprostone combined with polyethylene glycol electrolyte powder for bowel preparation in patients classified by risk level: a randomised trial.
(PubMed, Front Oncol)
- P4 | "However, in patients classified as low-risk, the addition of lubiprostone does not provides additional benefits. https://clinicaltrials.gov, identifier ChiCTR2400088155."
Journal • Anesthesia • Cardiovascular • CNS Disorders • Colorectal Cancer • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Movement Disorders • Orthopedics • Parkinson's Disease
October 03, 2025
Association between use of lubiprostone and headache: A systematic review and meta-analysis of randomized controlled trials.
(PubMed, Br J Clin Pharmacol)
- "The results of this meta-analysis suggest that lubiprostone treatment increases the risk of headache in adults."
Journal • Retrospective data • Review • Pain
September 29, 2025
Laxative logic: when lifestyle is not enough.
(PubMed, Curr Opin Gastroenterol)
- "Patients with constipation now have access to a wide range of medications, from over-the-counter osmotic and stimulant agents to prescription laxative combination strategies. This breadth allows clinicians to tailor therapy to diverse pathophysiology and symptom profiles. Yet despite this choice, real-world adherence remains poor and many patients are dissatisfied, reflecting the complexity of treating constipation and frequent mismatches between therapy and patients' most bothersome symptoms. Management should emphasize careful symptom assessment, shared decision-making, and clear expectation setting, while leveraging the available armamentarium."
Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
August 29, 2025
Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial.
(PubMed, Sci Adv)
- "Multiomics analysis revealed that lubiprostone modulated the gut microbial agmatine pathway and increased spermidine levels, thereby improving renal mitochondrial function. Lubiprostone is a previously unknown and safe therapeutic option to mitigate renal decline in CKD."
Clinical • Journal • P2 data • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease
1 to 25
Of
283
Go to page
1
2
3
4
5
6
7
8
9
10
11
12